NCT00818181已完成2 期
A Multicentre Open Label Safety Study of a Sublingual Specific Immunotherapy With a Solution of Birch Pollen Allergen Extract in Patients With Clinically Relevant Birch Pollen Allergy
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 73
- 试验地点
- 2
- 主要终点
- number of patients with at least one adverse event
研究概览
简要总结
This trial is performed to assess safety of a sublingual birch pollen extract.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 60 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Allergic rhinoconjunctivitis attributable to birch pollen
- •Positive SPT
- •Positive EAST
排除标准
- •Serious chronic diseases
- •Other perennial allergies
- •Partly controlled asthma
结局指标
主要结局
number of patients with at least one adverse event
时间窗: 8 months
Between Visit 03 and Visit 05 (June 2008 - January 2009)
次要结局
- Systemic reactions(Entire treatment period)
研究者
研究点 (2)
Loading locations...
相似试验
Unknown
3 期
Safety and Efficacy Study With Allergen Extracts of House Dust Mites for Specific Sublingual ImmunotherapyAllergic RhinitisNCT01014325Roxall Medizin130
已完成
3 期
Safety and Efficacy of Specific Immunotherapy With an Aluminium Hydroxide-adsorbed Allergoid Preparation of Birch Pollen AllergensPollen AllergyNCT00263627Allergopharma GmbH & Co. KG253
撤回
1 期
Safety Study of Intravitreal EBI-031 Given as a Single or Repeat Injection to Subjects With Diabetic Macular EdemaDiabetic Macular EdemaNCT02842541Eleven Biotherapeutics
已完成
3 期
A Study to Evaluate the Safety of Raptiva in Adults With Plaque Psoriasis Previously Enrolled in Study ACD2600gPsoriasisNCT00096603Genentech, Inc.450
Unknown
1 期
A Study to Evaluate the Safety and Efficacy of EscharEx (EX-02) in the Treatment of Basal Cell CarcinomaSuperficial Basal Cell CarcinomaNodular Basal Cell CarcinomaNCT05157763MediWound Ltd32